Access our latest insights & resources

No relief for PBMs [CVS (CVS), Cigna (CI),...

Delays in approvals due to disrupted work schedules at FDA because of the coronavirus...

Amid investor fears of competitive risks to Silk Road Medical’s (SILK)’s TCAR procedure...

Disrupted work schedules at FDA result in approval delays...

We expect the FDA to grant accelerated approval of Biogen's (BIIB) ALS treatment...

Size of Medicare Advantage mitigation may be less than earlier expectations...

How European Pharma fared versus consensus estimates...

Following Glaukos’ (GKOS) earnings report, attention now turns to the regulatory...

AXNX competitive pressures manageable following AMA disclosure...

No more than 50% odds to CMS forestalling an implied facility cut of 25%+ for SWAV's IVL procedures...